Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
diffuse large B-cell lymphoma treatment
market2 mentionslast seen Nov 4, 2026
Market for treatment of diffuse large B-cell lymphoma.
Relationships 1
Relationship
ZYNLONTAapplies todiffuse large B-cell lymphoma treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 4, 2026ADC Therapeutics SA 8-K: Item 2.02: Results of Operations and Financial Condition; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma
- filingSEC EDGAROct 13, 2026ADC Therapeutics SA 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.02: Results of Operations and Financial Condition; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL)